Multicenter, prospective, randomized controlled trial: accurate rTMS treatment of hand dysfunction in stroke and construction of multimodal functional outcome prediction model

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100047637

Enrollment

Unknown

Registered

2021-06-21

Start date

2021-06-17

Completion date

Unknown

Last updated

2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

1 Hz group:Repetitive transcranial magnetic stimulation with low-frequency stimulation group (1 Hz)

5 Hz group :Repetitive transcranial magnetic stimulation with high-frequency stimulation group (5 Hz)

10Hz group :Repetitive transcranial magnetic stimulation with high-frequency stimulation group (10 Hz)

20Hz group:Repetitive transcranial magnetic stimulation with high-frequency stimulation group (20 Hz)

Sham group:Pseudo-repetitive transcranial magnetic stimulation.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Meeting the diagnostic criteria for stroke developed at the 4th National Cerebrovascular Disease Conference; 2. Confirmed by CT or MRI examination for the first stroke, unilateral onset, with residual upper limb motor dysfunction, hand Brunnstrom stage II-V, modified Ashworth scale score <= grade III, normal upper limb motor function before this onset; 3. The duration of the disease was between 7 days and 12 months; 4. Vital signs were stable; 5. Patients and family members voluntarily participated and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pain and functional limitation of the affected upper limb due to other etiologies; 2. Recurrence of stroke or progression of various conditions; 3. There are contraindications to TMS such as metal, electrical device implants and cranial defects in the body when undergoing TMS screening questionnaires; 4. Personal or family history of epilepsy, or taking drugs that alter cortical excitability; 5. Those who have severe mental abnormalities, cognitive, speech, and hearing impairment and are unable to cooperate with the examination and treatment; 6. Combination of severe cardiopulmonary and other important organ insufficiencies; 7. Pregnant women.

Design outcomes

Primary

Measure	Time frame
Fugl-Meyer Assessment Upper Extremity Scale;Cerebral hemispheric motor evoked potentials;Serum brain-derived neurotrophic factor (BDNF) levels;	—

Countries

China

Contacts

Public ContactLiu Jing

Department of Rehabilitation Medicine,The First Affiliated Hospital of University of South China

410505633@qq.com+86 18673412081

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026